$1.96
+0.14 (+7.69%)
Open$1.83
Previous Close$1.82
Day High$1.96
Day Low$1.83
52W High$28.67
52W Low$10.08
Volume—
Avg Volume419.0K
Market Cap213.94M
P/E Ratio28.22
EPS$0.71
SectorBiotechnology
Analyst Ratings
Sell
13 analysts
Price Target
+986.7% upside
Current
$1.96
$1.96
Target
$21.30
$21.30
$14.71
$21.30 avg
$34.17
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 90.95M | 87.33M | 87.17M |
| Net Income | 6.08M | 8.20M | 6.12M |
| Profit Margin | 6.7% | 9.4% | 7.0% |
| EBITDA | 10.53M | 10.19M | 12.10M |
| Free Cash Flow | 5.16M | 6.96M | 5.08M |
| Rev Growth | -3.1% | +6.5% | -4.4% |
| Debt/Equity | 0.48 | 0.50 | 0.57 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |